AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance and preserves useful immune responses in inflammatory, autoimmune and degenerative diseases. Founded by a team with a long cutting-edge translational expertise in regulatory T cells and mechanisms of tolerance, AbolerIS Pharma is developing two innovative strategies to finely regulate the immune system: an anti-CD45RC monoclonal antibody and the cytokine IL-34.
AbolerIS Pharma received a pre-seed maturation funding from SATT Ouest-Valorisation and was incubated by Atlanpole Biotherapies, the regional competitiveness cluster. In November 2020, Company raised a 2,5M$ in Seed Financing from Newton Biocapital and Turenne Santé/Sham Innovation Santé.
In September 2021, it has been rewarded as one of the laureates at the 23rd national i-Lab innovation competition.